An 111In-labeled Fab fragment of trastuzumab was previously investigated in a phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma, revealing a terminal plasma half-life of 20.7 h [18]. This evidence concerns the gene ERBB2 and neoplasm.